Semglee's Boost On Express Scripts Formulary Reflects Interchangeability – And Rebates
Viatris’s Insulin Biosimilar Gets Preferred Status
First interchangeable insulin biosimilar gains preferred status on one of the largest national formularies in the US.
You may also be interested in...
Just-in-time education may be preferred, so patients and providers see it as they are making decisions, OTBB Director Sarah Yim says in an interview.
Craig Burton, who replaces the FDLI-bound Christine Simmon, tells the Pink Sheet that fighting rebating practices which harm insulin patients now can pave the way for successful launches of Humira biosimilars next year. Biosimilar markets should not be ‘winner-take-all,’ he says.
Hoping to bring a candidate for the alpha-1 disorder into the clinic in 2023, Korro’s latest funding is meant to enable development of a rare CNS disorder drug and a third drug for a more prevalent indication.